Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Management of EGFR mutated non-small cell lung carcinoma patients].

Revue des maladies respiratoires - 1 Nov 2022

Perquis M-P, Tissot C, Bouleftour W, Bayle-Bleuez S, Vercherin P, Forest F, Fournel P

Abstract excerpt

INTRODUCTION: Mutations in the epidermal growth factor receptor (EGFR) gene are commonly observed in non-small-cell lung cancer (NSCLC). Over the past decade, the management of NSCLC-carrying EGFR mutation has evolved considerably with the use of tyrosine kinase inhibitors (TKIs). The main objective of this retrospective study was to analyze the evolution of therapeutic strategies in a cohort of patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 36272856
DOI: 10.1016/j.rmr.2022.08.010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Management of EGFR mutated non-small cell lung carcinoma patients].PMID 36272856Read ↗

Management of EGFR mutated nonsmall cell lung carcinoma patients.Semantic proximity Read ↗

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016.Semantic proximity Read ↗

Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary managementSemantic proximity Read ↗

Beyond EGFR TKI in EGFR-mutant non-small cell lung cancer patients: main challenges still to be overcome.Semantic proximity Read ↗

Updates in the Management of EGFR-Mutated Non-small Cell Lung Cancer (NSCLC).Semantic proximity Read ↗

Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer.Semantic proximity Read ↗

[Changes in the diagnostic and therapeutic strategies of non-small cell lung cancer].Semantic proximity Read ↗

[Inhibitors of the EGFR pathway in non small cell lung cancer: what's new in 2007?].Semantic proximity Read ↗

[Advances of Molecular Targeted Therapy in EGFR-mutated Squamous Cell Lung Cancer].Semantic proximity Read ↗

Determining the appropriate treatment for different EGFR mutations in non-small cell lung cancer patients.Semantic proximity Read ↗

Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly.Semantic proximity Read ↗

Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.